Biodesix, Inc. operates a data-driven diagnostic solutions company in the United States. The company offers blood-based tests across the lung cancer continuum of care, such as Nodify XL2 and Nodify CDT tests to help physicians reclassify risk of malignancy in patients with suspicious lung nodules; and GeneStrat tumor profiling and VeriStrat immune profiling tests that provide physicians with timely results to facilitate treatment decisions. It also provides Bio-Rad SARS-CoV-2 ddPCR test, which is designed to detect the presence of infection by the SARS-CoV-2 virus; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. In addition, the company offers include diagnostic research, clinical research, development, and testing services to biopharmaceutical companies, as well as discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. Biodesix, Inc. was incorporated in 2005 and is headquartered in Boulder, Colorado.
IPO Year: 2020
Exchange: NASDAQ
Website: biodesix.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/14/2025 | Outperform → Mkt Perform | William Blair | |
| 9/16/2024 | Sector Outperform | Scotiabank | |
| 7/26/2024 | $3.00 | Buy | Craig Hallum |
| 5/13/2024 | $2.80 | Buy | TD Cowen |
| 5/3/2024 | $3.00 | Buy | Lake Street |
| 11/17/2021 | $21.00 → $11.00 | Overweight → Equal-Weight | Morgan Stanley |
LOUISVILLE, Colo., June 10, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, announced today that it is partnering with the Association of Pulmonary Advanced Practice Providers (APAPP) to bring new educational programs aimed at their professional membership to better provide access and timely care to patients at risk for lung cancer. In this novel partnership, the two organizations will launch new educational resources for Lung Health providers on innovative lung nodule risk assessment testing, such as the Nodify Lung® blood-based tests, or cancer treatment decision support testing, such as the IQLung® blood-based tests. According to the Ame
LOUISVILLE, Colo., May 22, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, announced today that new data will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois at 2:30 pm ET on Saturday, May 31st. The presentation titled "Host immune classifier to predict survival with chemoimmunotherapy in PD-L1 ≥50% metastatic NSCLC" features data from the INSIGHT study (NCT03289780) which enrolled greater than 5,000 patients with non-small cell lung cancer (NSCLC). The data will be presented by Dr. Vamsidhar Velcheti, MD, Director of Thoracic Oncology at NYU Langone's Perlmutter Cancer Center. The Ver
LOUISVILLE, Colo., May 21, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, today announced that members of the Biodesix management team, will participate in two upcoming investor conferences: 22nd Annual Craig-Hallum Institutional Investor Conference 1x1 MeetingsDate: Wednesday, May 28, 2025 Location: Minneapolis, MN 45th Annual William Blair Growth Stock Conference Presentation and 1x1 Meetings Date and Time: Wednesday, June 4, 2025 at 9:20 AM CTLocation: Chicago, IL The presentation will be webcast live and available for replay under "News & Events" in the Investors section of the Company's website at biodesix.com. About Biodesix Biodes
LOUISVILLE, Colo., May 15, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, announced that new data will be presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2025 Annual Meeting in Montreal, Quebec and at the American Thoracic Society (ATS) 2025 International Conference in San Francisco, California. The presentation titled "Time to Diagnosis of Lung Cancer from Identification of a Pulmonary Nodule in the United States" was presented yesterday by Kimberly Le, Biodesix Director of Health Economics and Outcomes Research at ISPOR 2025. This study included over 350,000 patients with medical claims for l
LOUISVILLE, Colo., May 14, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, is pleased to announce that it is a Colorado Top Workplaces 2025 Winner. The Top Workplaces program has an 18-year history of surveying and celebrating people-first organizations nationally and across 60 regional markets. This recognition is based solely on employee feedback gathered through a third-party survey, administered by employee engagement technology partner, Energage. The confidential survey uniquely measures the employee experience and its component themes, including employees feeling respected & supported, enabled to grow, and empowered to execute, to name
Total Q1 2025 Revenue of $18.0 million, an increase of 21% over Q1 2024; Gross margins of 79.4% for Q1 2025; Q1 2025 Net loss improved by 18% compared to Q1 2024; Updated 2025 Revenue Guidance to a range of $80-85 million; Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, Colo., May 13, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, today announced its financial and operating results for the first quarter ended March 31, 2025. "Our quarter was highlighted by continued progress toward our three key goals for 2025 – growing top line revenue, improving operational efficiencies and leverage, and advancing our pipeline," said Sc
LOUISVILLE, Colo., April 29, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the first quarter ended March 31, 2025 after the close of trading on Tuesday, May 13. Biodesix management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. Listeners can register for the webcast via this link. Analysts who wish to participate in the question and answer session should use this link. A replay of the webcast will be available via the company's investor website approximately two hours after the
LOUISVILLE, Colo. and HERCULES, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc (NASDAQ:BDSX), a leading diagnostics solutions company, and Bio-Rad Laboratories (NYSE:BIO), a global leader in life science research and diagnostics products, contributed to new research findings from Friends of Cancer Research's (Friends') ctMoniTR Project, recently published in Clinical Cancer Research (CCR). The findings demonstrate a strong association between changes in levels of circulating tumor DNA (ctDNA) and treatment outcomes, offering the potential for integration of ctDNA analysis in therapeutic development programs, and clinical cancer care. The ctMoniTR Project (ctDNA to Monitor Treatm
Total Revenue of $71.3 million for FY2024, growing 45% over FY2023; Gross margins of 78% for FY2024, up 5% points over FY2023; FY2025 Total Revenue Guidance of $92-95 million; Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, Colo., March 03, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, today announced its financial and operating results for the fourth quarter and year ended December 31, 2024 (fiscal 2024). "Biodesix concluded a strong 2024, advancing our key initiatives and delivering on our financial and operational goals," said Scott Hutton, Chief Executive Officer. "We exceeded our revenue targets, with total revenue re
BOULDER, Colo., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, today announced Scott Hutton, Chief Executive Officer, and Robin Cowie, Chief Financial Officer, will present in a fireside chat and host in-person 1x1 investor meetings at TD Cowen 45th Annual Health Care Conference on March 5, 2025. TD Cowen 45th Annual Health Care ConferenceFireside Chat Date: Wednesday, March 5, 2025Fireside Chat Time: 1:50 PM ETLocation: Boston, MA The presentation will be webcast live and available for replay under "News & Events" in the Investors section of the Company's website at biodesix.com. About Biodesix Biodesix is a leading diagnostic s